Cancer‐Associated Fibroblasts Promote Glucose Metabolic Reprogramming and Progression of Triple‐Negative Breast Cancer via Exosomal circFAD104‐Mediated Intercellular Communication
Aug 2026· Advancement of science· 0 citations· 57 references
Medicine
TL;DR
These findings uncover a CAF‐exosomal circFAD104 axis that reprograms glucose metabolism to drive TNBC progression via the circFAD104/MARCHF8/PGM1 pathway, highlighting its potential as a stroma‐targeted biomarker and prognostic predictor.
Abstract
ABSTRACT Triple‐negative breast cancer (TNBC) is characterized by high metastatic tendency and poor prognosis, largely driven by dynamic crosstalk between cancer cells and the tumor microenvironment (TME). Cancer‐associated fibroblasts (CAFs) are a major component of the TME, yet their functional contributions to TNBC progression remain incompletely understood. In this study, we isolated exosomes from patient‐derived CAFs and normal fibroblasts (NFs), and profiled their circRNA content using RNA sequencing. circFAD104 was significantly enriched in CAFs and their derived exosomes, with elevated stromal expression confirmed by qRT‐PCR and in situ hybridization (ISH). PKH26 labeling demonstrated that CAF‐derived exosomes efficiently deliver circFAD104 to TNBC cells, where it enhances cancer stemness, metastasis, and glycolysis. Mechanistically, circFAD104 acts as a molecular scaffold to promote the interaction between the E3 ubiquitin ligase MARCHF8 and its substrate PGM1, facilitating MARCHF8‐mediated K48‐linked ubiquitination and subsequent proteasomal degradation of PGM1. Loss of PGM1 redirects glucose flux from glycogen synthesis toward glycolysis, thereby fueling tumor progression. Clinically, high circFAD104 levels were correlated with poorer overall survival in breast cancer patients. These findings uncover a CAF‐exosomal circFAD104 axis that reprograms glucose metabolism to drive TNBC progression via the circFAD104/MARCHF8/PGM1 pathway, highlighting its potential as a stroma‐targeted biomarker and prognostic predictor.
ABSTRACT Breast cancer is the leading malignancy among women worldwide, with triple‐negative breast cancer (TNBC) representing the most aggressive subtype. Accumulating evidence highlights glucose metabolism reprogramming as a critical driver of TNBC progression and immune evasion, yet the underlying molecular mechanis...
Yuhan Jin, Wen-Jing Zhao, Lei Wang et al.· Advancement of science· 0 citations
Results show that NF‐tumor crosstalk is rapid, bidirectional and functionally relevant to MMC response in vitro, and NFs can rapidly acquire CAF‐like activation features following tumor‐derived stimulation and contribute to a stromal context associated with EMT‐like plasticity and reduced MMC‐induced cytotoxicity in vi...
Jin-Hui Gao, Cindy Xinyu Ji, Ci Ren et al.· Journal of cell communicatio...· 0 citations
It is demonstrated that treatment with the mTOR inhibitor rapamycin and the FDA-approved rapamycin analog everolimus effectively suppressed miR-1290-induced TNBC cell proliferation, suggesting a potential therapeutic strategy for TNBC.
Jinkwon Lee, Taesang Son, Gyeonghwa Kim et al.· Signal Transduction and Targ...· 0 citations
It is found that miR‐4435 was highly expressed in both CAFs‐ derived exos and GC tissues and was associated with TNM stage as well as tumor size in GC patients, and exos‐transfered miR‐4435 was highlighted as a potential therapeutic target in GC.
Ying-Ying Wang, Wen-Bo Liu, Zhi-Ran Yang et al.· The FASEB Journal· 0 citations
CAV1 is identified as a fibroblast-associated gene linked to stemness- and ferroptosis-related signatures and promoting bladder cancer progression by activating the LIF-STAT3 signaling axis.
A CAF-TAGLN/HGF/c-MET/DDX5/CAV1 signaling cascade linking stromal activation to tumor-cell transcriptional reprogramming and CAF-tumor crosstalk within the TME is defined to identify TAGLN as a potential therapeutic vulnerability for microenvironment-directed intervention in GC.
Qiang Li, Jia-Ning Yang, Lu-Hong Cao et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.